Akari Therapeutics, Plc Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs
Akari Therapeutics, Plc (AKTX) had Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs of $27.17 million as of 2015-09-30, per its 10-Q filed 2015-11-23.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs · last filed 2015-11-23
- 2015-09-30: Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs $27.17M.
- 2015-06-30: Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs $984.00K.
- 2015-03-31: Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs $774.00K.
- 2014-12-31: Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs $0.00; Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs as first filed $235.00K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs as first filed |
|---|---|---|
| 2015-09-30 | $27.17M 10-Q · filed 2015-11-23 | |
| 2015-06-30 | $984.00K 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $774.00K 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $0.00 10-Q · filed 2015-11-23 | $235.00K 10-K · filed 2015-02-11 |
| 2013-12-31 | $787.00K 10-Q · filed 2015-08-12 | |
| 2012-12-31 | $630.00K 10-K · filed 2015-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |